-
Boehringer Ingelheim Partners with Shanghai Handu Pharma to Enhance Oral Medication Delivery
•
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Shanghai Handu Pharmaceutical Technology Co., Ltd, a China-based company previously established as a wholly foreign-owned enterprise (WFOE) by Hong Kong WD Pharmaceutical Co., Ltd. The financial details of the agreement have not been disclosed. This collaboration aims…
-
Gedeon Richter Acquires Rights to Mithra’s Contraceptive and Menopause Treatments for Chinese Market
•
Gedeon Richter Plc, a Hungarian pharmaceutical company, and Belgium’s Mithra (OTCMKTS: MITPF) have entered into a licensing agreement that grants Gedeon the rights to develop and commercialize two of Mithra’s products in the Chinese market. The products in question are the oral contraceptive Estelle, which contains 15 mg estetrol (E4)…
-
Aspen Pharmacare Holdings to Boost China Presence with Full Acquisition of Sandoz’s Subsidiary
•
Aspen Pharmacare Holdings (JSE: APN), a South Africa-based pharmaceutical company, is poised to enhance its footprint in the Chinese market with the full acquisition of Sandoz’s (SWX: SDZ) China subsidiary, Sandoz (China) Pharmaceutical Co., Ltd. This acquisition will grant Aspen all commercial and intellectual property rights to the subsidiary’s existing…
-
AstraZeneca Halts Late-Stage Trials for Lokelma in Hyperkalemia Due to Timing and Event Rate Issues
•
AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, has announced the termination of two late-stage trials for its commercial-stage potassium binder, Lokelma (sodium zirconium cyclosilicate), in hyperkalemia (HK) across the cardiorenal spectrum. The company has clarified that the decision is not due to safety concerns and does not affect…
-
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
•
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech firm Carmot Therapeutics, a specialist in anti-obesity and diabetes drugs, in a transaction valued at USD 2.7 billion with potential milestone payments of up to USD 400 million. The acquisition is expected to close in…
-
Stem-Cell Startup Xellsmart Earns FDA Orphan Drug Designation for ALS Therapy
•
Xellsmart, a stem-cell startup headquartered in Suzhou, has announced that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its induced pluripotent stem cell (iPSC) derived subtype neural precursor cell therapy, targeting amyotrophic lateral sclerosis (ALS). ALS is a devastating motor neuron disease…
-
Worg Pharmaceuticals Gets FDA Approval for Phase II Graves’ Disease Study
•
Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has received the green light from the US Food and Drug Administration (FDA) to proceed with a Phase II clinical study for its drug candidate WP1302 in the treatment of Graves’ disease. Graves’ disease, a prevalent autoimmune condition, impacts an estimated 10…
-
Nanchang Baiji Pharmaceutical’s Budesonide Nasal Spray Approved by China’s NMPA
•
Nanchang Baiji Pharmaceutical Co. Ltd., a Chinese pharmaceutical company, has received approval from the National Medical Products Administration (NMPA) for its generic budesonide nasal spray. The product is indicated for the treatment of seasonal and perennial allergic rhinitis, as well as perennial non-allergic rhinitis, and for the prevention of nasal…
